Table of Contents

company-logo

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Kintara Therapeutics Dividend Announcement

• Kintara Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Kintara Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Kintara Therapeutics Dividend History

Kintara Therapeutics Dividend Yield

Kintara Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Kintara Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Kintara Therapeutics Financial Ratios

P/E ratio-0.07
PEG ratio0.00
P/B ratio0.15
ROE-454.05%
Payout ratio-0.07%
Current ratio2.45
Quick ratio2.45
Cash Ratio2.17

Kintara Therapeutics Dividend FAQ

Does Kintara Therapeutics stock pay dividends?
Kintara Therapeutics does not currently pay dividends to its shareholders.
Has Kintara Therapeutics ever paid a dividend?
No, Kintara Therapeutics has no a history of paying dividends to its shareholders. Kintara Therapeutics is not known for its dividend payments.
Why doesn't Kintara Therapeutics pay dividends?
There are several potential reasons why Kintara Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Kintara Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Kintara Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Kintara Therapeutics a dividend aristocrat?
Kintara Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Kintara Therapeutics a dividend king?
Kintara Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Kintara Therapeutics a dividend stock?
No, Kintara Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Kintara Therapeutics stocks?
To buy Kintara Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Kintara Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.